Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexrazoxane Hydrochloride

FDA-approved product (injectable, injection), marketed as Dexrazoxane Hydrochloride, Totect, Zinecard.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Dexrazoxane Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Cardiomyopathy
  • Extravasation of Diagnostic and Therapeutic Materials

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Dexrazoxane Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexrazoxane Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexrazoxane Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

    NCT00005578 · start 1997-03

    Registered record
    Registry ID
    NCT00005578
    Conditions
    Cardiac Toxicity; Lymphoma
    Interventions
    bleomycin sulfate; filgrastim; cyclophosphamide; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; prednisone; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-03
    Completion
    2008-06
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Lymphoma
    Interventionbleomycin sulfate; filgrastim; cyclophosphamide; dexrazoxane hydrochloride +5 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

    NCT00002827 · start 1996-10

    Registered record
    Registry ID
    NCT00002827
    Conditions
    Cardiac Toxicity; Lymphoma
    Interventions
    bleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET electron therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-10
    Completion
    2008-06
    Enrolment
    294

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Lymphoma
    Interventionbleomycin sulfate; filgrastim; dexrazoxane hydrochloride; doxorubicin hydrochloride +5 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

    NCT01230983 · start 1996-06

    Registered record
    Registry ID
    NCT01230983
    Conditions
    Cardiac Toxicity; Leukemia; Lymphoma
    Interventions
    asparaginase; cytarabine; dexrazoxane hydrochloride; doxorubicin hydrochloride; leucovorin calcium; mercaptopurine; methotrexate; prednisone; therapeutic hydrocortisone; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-06
    Completion
    2004-10
    Enrolment
    573

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Toxicity; Leukemia; Lymphoma
    Interventionasparaginase; cytarabine; dexrazoxane hydrochloride; doxorubicin hydrochloride +7 more
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Childhood Acute Lymphoblastic Leukemia

    NCT00165087 · start 1996-01

    Registered record
    Registry ID
    NCT00165087
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    asparaginase (E. Coli); asparaginase (Erwina); dexrazoxane; doxorubicin; cranial radiation (once daily fractionation); cranial radiation (twice-daily fractionation); Intrathecal chemotherapy without radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    1996-01
    Completion
    2006-09
    Enrolment
    491

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    Interventionasparaginase (E. Coli); asparaginase (Erwina); dexrazoxane; doxorubicin +3 more
    PhasePhase 3
    Registry statusTerminated

  • New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

    NCT00001335 · start 1993-04

    Registered record
    Registry ID
    NCT00001335
    Conditions
    Ewing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma
    Interventions
    ADR-529; Topotecan; G-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1993-04
    Completion
    2002-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing's Sarcoma; Neuroblastoma; Rhabdomyosarcoma
    InterventionADR-529; Topotecan; G-CSF
    PhasePhase 2
    Registry statusCompleted